Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

https://financialpost.com/globe-newswire/biogen-initiates-phase-3-study-of-felzartamab-for-the-treatment-of-late-antibody-mediated-rejection-amr-in-kidney-transplant-patients